SAREPTA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 131.8 USD | -0.36% |
|
-1.38% | +36.70% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 1.9B | Sales 2025 * | 2.76B | Capitalization | 12.46B |
|---|---|---|---|---|---|
| Net income 2024 * | 266M | Net income 2025 * | 883M | EV / Sales 2024 * | 6.02 x |
| Net cash position 2024 * | 1.03B | Net cash position 2025 * | 2.54B | EV / Sales 2025 * | 3.59 x |
| P/E ratio 2024 * |
40.8
x | P/E ratio 2025 * |
13
x | Employees | 1,314 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.11% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sarepta Therapeutics, Inc.
More recommendations
More press releases
More news
| 1 day | -0.36% | ||
| 1 week | -1.38% | ||
| Current month | +4.07% | ||
| 1 month | +4.36% | ||
| 3 months | +3.90% | ||
| 6 months | +65.92% | ||
| Current year | +36.70% |
1 week
129.44
146.68
1 month
114.37146.68
Current year
91.34146.68
1 year
55.25159.89
3 years
55.25159.89
5 years
55.25181.83
10 years
8.00181.83
| Managers | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.63% | 0 M€ | -2.17% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 131.8 | -0.36% | 735,589 |
| 24-05-09 | 132.3 | -0.21% | 1,279,163 |
| 24-05-08 | 132.6 | -2.54% | 1,579,021 |
| 24-05-07 | 136 | +0.74% | 2,003,305 |
| 24-05-06 | 135 | +1.03% | 823,447 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Calendar
2024-06-06
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
131.8
USD
Average target price
165.9
USD
Spread / Average Target
+25.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +36.70% | 12.46B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +295.70% | 8.12B |
- Stock Market
- Equities
- SRPT Stock
